Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy

Myocardial Protection With Esmolol in Patients With Hypertrophic Obstructive Cardiomyopathy Undergoing Surgery Under Cardiopulmonary Bypass

Perioperative blockage of beta-adrenoreceptors is widely used in cardiac and non-cardiac surgery to reduce the rate of cardiovascular complications. Several randomized-controlled studies and meta-analysis showed that esmolol reduces the incidence of myocardial ischemia and arrhythmias in cardiac surgery as well as enhances postoperative cardiac performance. No studies assessed the influence of esmolol in patients with hypertrophic obstructive cardiomyopathy undergoing cardiac surgery.

Inclusion Criteria:

• Age > 18 years
• Signed informed consent
• Patient with hypertrophic obstructive cardiomyopathy undergoing surgery under cardiopulmonary bypass

Exclusion Criteria:

• History of adverse effects on esmolol
• Urgent/emergent surgery
• Administration of esmolol in 30 days before randomization
• Participation in other randomized trial during same hospitalization